Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Integrated Dna Technologies Inc. has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters span 6 distinct examiners and 4 distinct art units, showing examiner diversity alongside recurring art-unit assignments. The portfolio benefits from centralized tracking of art-unit developments and separate examiner-specific response planning.
OYEYEMI, OLAYINKA A is the busiest examiner, with 2 pending matters. That examiner carries the largest stated assignment, while the remaining matters are spread across the other examination channels.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 5 (83%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAMIREZ, DELIA M | 1 | 65.1% | +56.3% |
| OYEYEMI, OLAYINKA A | 1 | 60.4% | +46.5% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.8% |
| HORLICK, KENNETH R | 1 | 79.0% | +15.3% |
| RYAN, DOUGLAS CHARLES | 1 | 38.2% | +48.4% |
| HUTSON, RICHARD G | 1 | 65.1% | +52.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18908672 | OPTIMIZED PROTEIN FUSIONS AND LINKERS | RAMIREZ, DELIA M | — |
| 18613719 | USE OF A 53BP1 BINDING HUMAN UBIQUITIN VARIANT TO IMPROVE RATES OF HDR IN MULTIPLE CELL TYPES | WILSON, MICHAEL C | — |
| 18417992 | METHODS FOR VARIANT DETECTION | HORLICK, KENNETH R | — |
| 18404826 | CRISPR-BASED COMPOSITIONS AND METHODS OF USE | RYAN, DOUGLAS CHARLES | — |
| 18176091 | C-TERMINAL PEPTIDE EXTENSIONS WITH INCREASED ACTIVITY | HUTSON, RICHARD G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18908672 | OPTIMIZED PROTEIN FUSIONS AND LINKERS | RAMIREZ, DELIA M | — |
| 18816789 | METHODS FOR VARIANT DETECTION | OYEYEMI, OLAYINKA A | — |
| 18613719 | USE OF A 53BP1 BINDING HUMAN UBIQUITIN VARIANT TO IMPROVE RATES OF HDR IN MULTIPLE CELL TYPES | WILSON, MICHAEL C | — |
| 18417992 | METHODS FOR VARIANT DETECTION | HORLICK, KENNETH R | — |
| 18404826 | CRISPR-BASED COMPOSITIONS AND METHODS OF USE | RYAN, DOUGLAS CHARLES | — |
| 18176091 | C-TERMINAL PEPTIDE EXTENSIONS WITH INCREASED ACTIVITY | HUTSON, RICHARD G | — |
| Art Unit | Apps |
|---|---|
| 1652 | 2 |
| 1681 | 2 |
| 1638 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18908672 | OPTIMIZED PROTEIN FUSIONS AND LINKERS | RAMIREZ, DELIA M | 1652 | §102§103§112Other | Non-Final OA | — | Pending | Oct 07, 2024 |
| 18816789 | METHODS FOR VARIANT DETECTION | OYEYEMI, OLAYINKA A | 1681 | §103§112DP | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18613719 | USE OF A 53BP1 BINDING HUMAN UBIQUITIN VARIANT TO IMPROVE RATES OF HDR IN MULTIPLE CELL TYPES | WILSON, MICHAEL C | 1638 | §102§103§112 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18417992 | METHODS FOR VARIANT DETECTION | HORLICK, KENNETH R | 1681 | §102§103§112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18404826 | CRISPR-BASED COMPOSITIONS AND METHODS OF USE | RYAN, DOUGLAS CHARLES | 1635 | §103§112 | Non-Final OA | — | Pending | Jan 04, 2024 |
| 18176091 | C-TERMINAL PEPTIDE EXTENSIONS WITH INCREASED ACTIVITY | HUTSON, RICHARD G | 1652 | §102§112 | Final Rejection | — | Pending | Feb 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIntegrated Dna Technologies Inc. has 6 pending office actions as of October 2026, spread across 4 art units and 6 examiners.
Delia M Ramirez has the most, with 1 of Integrated Dna Technologies Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
